Company Information

  

Address: 3928 POINT EDEN WAY  
City: HAYWARD 
State: CA 
Zip Code: 94545 
Telephone: 650-489-9000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Specifically, we target well-characterized biological pathways with significant scientific data supporting their importance in regulating the immune response against cancer and for which either there are no molecules in development or those that exist have suboptimal profiles. To exploit these pathways, we have built a robust and highly efficient discovery capability to create and optimize highly differentiated small-molecule immuno-oncology product candidates. Since our inception in 2015, we have built a broad portfolio of small-molecule and antibody product candidates that we plan to develop together as intra-portfolio combinations. Our most advanced small-molecule product candidate, AB928, is in a Phase 1/1b program to evaluate it in combination with chemotherapy and with our anti-PD-1 antibody, AB122.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2019-0.47NAN/E
12/2018-1.43NAN/E
06/20189.24NA1.32

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2018 Leverage 2018
Net Inc/Comm Equity-0.14Total Liab/Total Assets0.15
Net Inc/Total Assets-0.18Total Liab/Inv Cap0.15
Net Inc/Inv Cap-0.19Total Liab/Comm Equity0.11
Pretax Inc/Net Sales-5.94Interest Coverage RatioNA
Net Inc/Net Sales-5.94Curr Debt/EquityNA
Cash Flow/Net Sales-5.15LTD/EquityNA
SG&A/NetSales1.62Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover154.69Quick Ratio15.29
Inventory TurnoverNACurrent Ratio15.29
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.03Inv/Curr AssetsNA
Net Sales/PP&E0.75  

Income Statement (Millions)

  3/31/2019 12/31/2018 9/30/2018 6/30/2018
Total Revenues(Net Sales) 1.75 1.56 4.29 1.25
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 4.97 3.61 3.58 3.45
Operating Income -18.77 -13.48 -12.14 -15.90
Interest Exp NA NA NA NA
Pretax Income -17.67 -12.30 -10.81 -13.53
Other Income 1.53 NA 1.33 2.14
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -17.67 -12.30 -10.81 -13.53

Balance Sheet (Millions)

Assets 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Cash & Short Term Investments 241.94 256.54 257.84 265.70
Receivables - Total 0.00 0.08 5.11 0.19
Inventories - Total NA NA NA NA
Total Current Assets 245.02 258.95 265.28 267.44
Net Property, Plant & Equipment 11.03 11.11 11.76 12.51
Total Assets 258.53 274.93 286.72 293.87
Liabilities        
Accounts Payable 10.46 9.13 8.78 9.73
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 19.00 16.94 16.61 16.38
Long-Term Debt NA NA NA NA
Total Liabilities 36.96 39.98 41.60 39.29
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -138.29 -122.83 -110.53 -99.72
Treasury Stock NA NA NA NA
Total Stockholders' Equity 221.57 234.94 245.12 254.57
Total Liabilities and Stockholders' Equity 258.53 274.93 286.72 293.87

Cash Flow Summary (Millions)

Categories 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Net Cash Provided by Operating Activities -16.84 -7.11 -11.77 -10.88
Net Cash Provided by Investing Activities 14.28 2.51 -83.34 -16.12
Net Cash Provided by Financing Activities -0.01 0.77 -0.01 -1.12

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20160.00-17.97--
12/20171.41-53.08--
12/20188.35-49.59-1.43
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/197520,74946.59




Report Date : 6/17/2019

Powered By Edgar Online © 2019EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.